ALKS

45.9200.56%
JR

Joshua Reed

Senior VP & CFO

Mr. Joshua Reed, M.B.A., is Chief Financial Officer of Alkermes plc from September 15, 2025 and serves as its Senior Vice President having joined in 2025. He served as Chief Financial Officer at Omega Therapeutics, Inc. (formerly known as VL42, Inc.) since 23 May 2022 until May 31, 2024.He serves as an Independent Director at Scholar Rock Holding Corporation since March 2021. He had been Chief Financial Officer of Aldeyra Therapeutics, Inc. since July 31, 2018 until May 10, 2022 and served as its Treasurer until May 10, 2022. Mr. Reed is a highly accomplished leader in the biopharmaceutical industry with many years of financial operations, strategy and investment banking experience. Prior to joining Aldeyra Therapeutics, Inc, he served as Vice President and Head of Finance for Bristol-Myers Squibb?s (BMS) United States and Puerto Rico operations from June 2016 to July 2018. From September 2013 to June 2016, Mr. Reed served as Executive Director, Corporate Financial Analysis for BMS. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions and Chase Manhattan Bank. Mr. Reed received a B. S. in Finance from Rutgers University and an M. B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan?s Ross School of Business.

Positions